153 related articles for article (PubMed ID: 31549881)
41. Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: No association with prognosis identified in 3-year follow-up.
Toomey D; Smyth G; Condron C; Kelly J; Byrne AM; Kay E; Conroy RM; Broe P; Bouchier-Hayes D
Int J Cancer; 2003 Jan; 103(3):408-12. PubMed ID: 12471625
[TBL] [Abstract][Full Text] [Related]
42. A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer.
Hernández-Prieto S; Romera A; Ferrer M; Subiza JL; López-Asenjo JA; Jarabo JR; Gómez AM; Molina EM; Puente J; González-Larriba JL; Hernando F; Pérez-Villamil B; Díaz-Rubio E; Sanz-Ortega J
Clin Transl Oncol; 2015 Apr; 17(4):330-8. PubMed ID: 25301404
[TBL] [Abstract][Full Text] [Related]
43. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
44. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.
Berghmans T; Ameye L; Willems L; Paesmans M; Mascaux C; Lafitte JJ; Meert AP; Scherpereel A; Cortot AB; Cstoth I; Dernies T; Toussaint L; Leclercq N; Sculier JP;
Lung Cancer; 2013 Nov; 82(2):340-5. PubMed ID: 24007627
[TBL] [Abstract][Full Text] [Related]
45. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer.
Jin Y; Zhang P; Li J; Zhao J; Liu C; Yang F; Yang D; Gao A; Lin W; Ma X; Sun Y
Int J Clin Exp Pathol; 2015; 8(11):13987-95. PubMed ID: 26823710
[TBL] [Abstract][Full Text] [Related]
46. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
47. HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
Cheng H; Janakiram M; Borczuk A; Lin J; Qiu W; Liu H; Chinai JM; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2017 Feb; 23(3):825-832. PubMed ID: 27553831
[TBL] [Abstract][Full Text] [Related]
48. Role for High-Affinity IgE Receptor in Prognosis of Lung Adenocarcinoma Patients.
Ly D; Zhu CQ; Cabanero M; Tsao MS; Zhang L
Cancer Immunol Res; 2017 Sep; 5(9):821-829. PubMed ID: 28775209
[TBL] [Abstract][Full Text] [Related]
49. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.
Usó M; Jantus-Lewintre E; Bremnes RM; Calabuig S; Blasco A; Pastor E; Borreda I; Molina-Pinelo S; Paz-Ares L; Guijarro R; Martorell M; Forteza J; Camps C; Sirera R
Oncotarget; 2016 Aug; 7(33):52849-52861. PubMed ID: 27463005
[TBL] [Abstract][Full Text] [Related]
50. Clinical evaluation of microRNA expression profiling in non small cell lung cancer.
Markou A; Sourvinou I; Vorkas PA; Yousef GM; Lianidou E
Lung Cancer; 2013 Sep; 81(3):388-396. PubMed ID: 23756108
[TBL] [Abstract][Full Text] [Related]
51. The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.
Talebian Yazdi M; van Riet S; van Schadewijk A; Fiocco M; van Hall T; Taube C; Hiemstra PS; van der Burg SH
Oncotarget; 2016 Jan; 7(3):3477-88. PubMed ID: 26658106
[TBL] [Abstract][Full Text] [Related]
52. Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer.
Donnem T; Al-Shibli K; Andersen S; Al-Saad S; Busund LT; Bremnes RM
Cancer; 2010 Sep; 116(18):4318-25. PubMed ID: 20549821
[TBL] [Abstract][Full Text] [Related]
53. Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.
Bense RD; Sotiriou C; Piccart-Gebhart MJ; Haanen JBAG; van Vugt MATM; de Vries EGE; Schröder CP; Fehrmann RSN
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27737921
[TBL] [Abstract][Full Text] [Related]
54. Heterogeneity of CD8
Obeid JM; Wages NA; Hu Y; Deacon DH; Slingluff CL
Cancer Immunol Immunother; 2017 Jan; 66(1):33-43. PubMed ID: 27770170
[TBL] [Abstract][Full Text] [Related]
55. Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.
Buhl IK; Santoni-Rugiu E; Ravn J; Hansen A; Christensen IJ; Jensen T; Pratt B; Askaa J; Jensen PB; Knudsen S; Sørensen JB
PLoS One; 2018; 13(3):e0194609. PubMed ID: 29566065
[TBL] [Abstract][Full Text] [Related]
56. Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer.
Võsa U; Vooder T; Kolde R; Fischer K; Välk K; Tõnisson N; Roosipuu R; Vilo J; Metspalu A; Annilo T
Genes Chromosomes Cancer; 2011 Oct; 50(10):812-22. PubMed ID: 21748820
[TBL] [Abstract][Full Text] [Related]
57. Molecular gene signature and prognosis of non-small cell lung cancer.
Huang P; Cheng CL; Chang YH; Liu CH; Hsu YC; Chen JS; Chang GC; Ho BC; Su KY; Chen HY; Yu SL
Oncotarget; 2016 Aug; 7(32):51898-51907. PubMed ID: 27437769
[TBL] [Abstract][Full Text] [Related]
58. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
[TBL] [Abstract][Full Text] [Related]
59. Clinical significance of the frequency of regulatory T cells in regional lymph node lymphocytes as a prognostic factor for non-small-cell lung cancer.
Hanagiri T; Shigematsu Y; Shinohara S; Takenaka M; Oka S; Chikaishi Y; Nagata Y; Iwata T; Uramoto H; So T; Tanaka F
Lung Cancer; 2013 Sep; 81(3):475-479. PubMed ID: 23891508
[TBL] [Abstract][Full Text] [Related]
60. Immune signature of tumor-infiltrating immune cells predicts the prognosis and therapeutic effects in squamous cell carcinoma.
Che Y; Luo Z; Zhang C; Sun N; Gao S; He J
Int Immunopharmacol; 2020 Oct; 87():106802. PubMed ID: 32745903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
